Compare Abeona Therapeutics Inc (ABEO) vs PAGSEG Inc (PAGS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs PAGSEG Inc — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while PAGSEG Inc trades at $8.73 (market cap $2.49B). The key difference: PAGSEG Inc is far larger — about 6.7× Abeona Therapeutics Inc's market cap, and PAGSEG Inc pays a 11.69% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | PAGS | |
|---|---|---|
Market Cap | $373.32M | $2.49B |
Sector | Health | Technology |
52-Week High | $7.23 | $12.00 |
52-Week Low | $4.17 | $7.75 |
Enterprise Value | $228.22M | $10.12B |
Dividend Yield | — | 11.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
PAGS trades at $8.93, down 2.08% for the day, with a bearish technical signal from moving averages. The stock shows strong value fundamentals with a P/E of 6.32 and P/B of 0.89. Recent earnings were mixed, missing in Q1 2026 but beating in Q4 2025. The company maintains solid profitability with a 10.4% net income margin and generated positive net cash flow of $930 million in 2025. A dividend of $0.26 per share is scheduled for payment on June 1, 2026.
The investment outlook is supported by deep valuation discounts and analyst optimism, with 15 buy ratings. However, near-term headwinds include flat payment volume growth and pressure from Brazilian interest rates. The primary risk remains macroeconomic sensitivity in Brazil, while the opportunity lies in potential expansion of banking and credit operations driving future earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About PAGSEG Inc
PagSeguro Digital Ltd. is a leading provider of financial technology solutions in Brazil, primarily focused on e-commerce, face-to-face transactions, and financial services. The company's main offerings include PagBank, a digital banking platform, and PagSeguro, a suite of payment processing solutions that includes point-of-sale devices and online payment gateways. PAGS targets micro-merchants, small and medium-sized enterprises (SMEs), and consumers, aiming to democratize access to financial services in the country.
Read more on PAGS →
